₹ 6.3 Cr
Volume Transacted
(Nov 7, 2024)
64.7 K
Stocks Traded
(Nov 7, 2024)
Last Updated on: Nov 08, 2024
Zydus Lifesciences Ltd
NSE: ZYDUSLIFE
YEARLOW
₹ 598.05
Last updated on: Nov 07, 2024
Open Demat Account
Enter your mobile no. to continue
+91
*By signing up you agree to our terms & conditions
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
No data available
* All values are consolidated
Last Updated time:
The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.
1M
1Y
3Y
5Y
Date | Price (₹) | Day Open (₹) | Day High (₹) | Day Low (₹) |
---|
07 Nov 2024 | 972.6 | 1009.8 | 1009.8 | 969.3 |
06 Nov 2024 | 995 | 988.5 | 1003.45 | 987.25 |
05 Nov 2024 | 989.3 | 1002.65 | 1006 | 970.05 |
04 Nov 2024 | 1004.3 | 1007 | 1011.85 | 994.45 |
01 Nov 2024 | 1004 | 1002.05 | 1014.3 | 998.95 |
31 Oct 2024 | 1001.85 | 985 | 1003.75 | 985 |
30 Oct 2024 | 985.55 | 1007.4 | 1007.4 | 982.8 |
29 Oct 2024 | 1002.3 | 1020 | 1020 | 988.3 |
28 Oct 2024 | 1006.65 | 993.5 | 1016.25 | 977.2 |
25 Oct 2024 | 990.2 | 1013.95 | 1013.95 | 986.45 |
Date | Price (₹) |
---|---|
07 Nov 2024 | 972.6 |
06 Nov 2024 | 995 |
05 Nov 2024 | 989.3 |
04 Nov 2024 | 1004.3 |
01 Nov 2024 | 1004 |
31 Oct 2024 | 1001.85 |
30 Oct 2024 | 985.55 |
29 Oct 2024 | 1002.3 |
28 Oct 2024 | 1006.65 |
25 Oct 2024 | 990.2 |
Market Value
₹ 0
Asset Value
₹ 0
* All values are in Rupees
Historical Revenue of Zydus Lifesciences Ltd
Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services.\r\r\n\r\r\nTypes of Revenue:\r\r\n\r\r\n1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered.\r\r\n\r\r\n2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees.\r\r\n\r\r\nFormula for Revenue:\r\r\n\r\r\nThe formula for calculating revenue is based on two goods & services:\r\r\n\r\r\nFor goods:\r\r\nRevenue = Avg unit price x Number of Units sold\r\r\n\r\r\nFor services:\r\r\nRevenue = Avg unit price x Number of Customers served.
No data available
* All values are in ₹ crore
Historical Net Profit of Zydus Lifesciences Ltd
Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions.\r\r\n\r\r\nNet Profit formula is expressed as:\r\r\n\r\r\nNet Profit = Total Revenue - Total Expense\r\r\n\r\r\nNet Profit Margin Ratio:\r\r\n\r\r\nNet Profit Margin Ratio = Net Profit / Total Revenue
No data available
* All values are in ₹ crore
Zydus Lifesciences to table results
Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 12 Nove...
31 Oct 202411:58
Zydus Life rises on in-principle approval from WHO for typhoid vaccine
ZyVac TCV is now eligible for purchase by United Nations (UN) agencies. It is indigenously...
23 Oct 202414:50
Zydus receives USFDA approval for Fludrocortisone Acetate Tablets
Zydus Lifesciences has received final approval from the United States Food and Drug Admini...
18 Oct 202409:29
Zydus Life gets final approval from USFDA for Fludrocortisone Acetate tab
Fludrocortisone Acetate tablets are indicated as partial replacement therapy for primary a...
18 Oct 202412:47
Zydus partners with ICMR to initiate Phase 2 clinical trials of Desidustat oral tablet for treating sickle cell disease
Zydus Lifesciences has formalized the Memorandum of Agreement (MoA) with Indian Council of...
15 Oct 202410:08
Zydus Life gets final approval from USFDA for Paliperidone drug
Paliperidone extended-release tablets are indicated for the acute and maintenance treatmen...
10 Oct 202414:51
FAQs for 52 Week Low of Zydus Lifesciences Ltd
Why is it important to track the 52-week low of Zydus Lifesciences Ltd stocks?
What factors can lead to Zydus Lifesciences Ltd stocks hitting a 52-week low?
Should investors buy Zydus Lifesciences Ltd stocks when they hit a 52-week low?
How often should investors monitor the 52-week low of Zydus Lifesciences Ltd stocks?
How can an investor assess the risk of buying Zydus Lifesciences Ltd stock at their 52-week low?
Should investors consider the overall market trend when evaluating Zydus Lifesciences Ltd stocks at their 52-week low?
Unlimited trading at just
Rs. 199*